Search

Displaying results 881 - 890 of 4238 in total
  1. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    as extreme terminal digit bias and the duplication of blocks of patient records. … [L36763,A238929] In addition, the use of aggregate patient data in large-scale meta-analyses (as opposed to individual patient data (IPD)) has been shown to disguise otherwise blatant data errors, such

  2. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate

  3. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)

  4. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  5. Drug

    Phenylephrine

    go.drugbank.com/drugs/DB00388
    ApprovedInvestigational

    Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension, dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Pheny...

    Categories: Sympathomimetics Used as Decongestants
  6. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract [A32280]. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as

  7. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery

  8. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.

  9. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … While systemic corticosteroids and other immunosuppressive agents are commonly used as first-line treatments to manage aGvHD, about 30-50% of patients with aGvHD experience inadequately control of disease

  10. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.